During the past decade, Sichuan Cancer Hospital conducted 77 clinical trials. In the 10-year time frame, 77 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 62 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sichuan Cancer Hospital" #1 sponsor was "Sichuan Cancer Hospital and Research Institute" with 15 trials, followed by "Hoffmann-La Roche" with 8 trials sponsored, "Janssen Research & Development, LLC" with 6 trials sponsored, "BeiGene" with 5 trials sponsored and "Shanghai Junshi Bioscience Co., Ltd." with 5 trials sponsored. Other sponsors include 36 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sichuan Cancer Hospital" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator, "Jiangsu HengRui Medicine Co., Ltd." with 3 trials as a collaborator, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 2 trials as a collaborator, "Atridia Pty Ltd." with 1 trials as a collaborator and "Chinese Southwest Oncology Group" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Sichuan Cancer Hospital" are "Nasopharyngeal Carcinoma" (6 trials), "Carcinoma, Non-Small-Cell Lung" (4 trials), "Non-Small Cell Lung Cancer" (4 trials), "Breast Neoplasms" (3 trials) and "Gastric Cancer" (3 trials). Many other conditions were trialed in "Sichuan Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Sichuan Cancer Hospital" are "Drug" (73 trials), "Radiation" (8 trials), "Biological" (4 trials), "Procedure" (3 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Docetaxel" (6 trials), "Amivantamab" (5 trials), "Cisplatin" (5 trials) and "Lazertinib" (5 trials). Other intervention names were less common.

The vast majority of trials in "Sichuan Cancer Hospital" are 73 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Sichuan Cancer Hospital". 4 are not yet recruiting, 41 are recruiting, 19 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Sichuan Cancer Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Sichuan Cancer Hospital, 14 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 34 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".